Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca PLC · Now $185.67
+1.5% in 1d after detection
Post-detection moves
1h
—
1d
+1.5%
3d
+1.3%
7d
+0.6%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS